Showing 6791-6800 of 7932 results for "".
- FDA Clears Sebacia Microparticles for Laser-Based Acne Treatmenthttps://practicaldermatology.com/news/fda-clears-sebacia-microparticles-for-laser-based-acne-treatment/2457603/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic
- Kuleana Debuts Natural, Reef-Safe Sunscreenhttps://practicaldermatology.com/news/kuleana-debuts-natural-reef-safe-sunscreen/2457601/Amid growing concerns that certain sunscreen ingredients are harming coral reefs and marine life, Hawaiian company Kuleana is rolling out a natural sunscreen that is free from oxybenzone and octinoxate – two chemicals known to be toxic to corals and other marine life that were recently bann
- Neova Launches New Line of Professional Grade Peelshttps://practicaldermatology.com/news/neova-launches-new-line-of-professional-grade-peels/2457604/Neova SmartSkinCare has introduced a new range of Professional Treatments developed exclusively for dermatologist use. The line of five new exfoliating peels integrate the newest and most advanced formulas with proven, established ingredients to produce visible results with minimal irritation and
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women wit
- Breaking Business News: Allergan Acquires Bontihttps://practicaldermatology.com/news/breaking-business-news-allergan-aquires-bonti/2457610/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global
- Allergan Launches Spotlyte: Digital Hub Will Educate Consumers About Medical Aesthetic Treatmentshttps://practicaldermatology.com/news/allergan-launches-spotlyte/2457615/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines.
- Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foamhttps://practicaldermatology.com/news/foamix-positive-topline-phase-3-results-for-topical-minocycline-foam/2457614/Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline results of the clinical trial (FX2017-22), which met both co-prim
- Business News: Candela Acquires Ellipsehttps://practicaldermatology.com/news/business-news-candela-acquires-ellipse/2457616/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Bee Venom May Help Treat Eczemahttps://practicaldermatology.com/news/bee-venom-may-help-treat-eczema/2457619/Bee venom and its major component, melittin, may be effective treatments for atopic dermatitis, according to a British Journal of Pharmacology study. Through studies conducted in mice and in human cells, inv